SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that the United States Adopted Names (USAN) Council has approved the nonproprietary name “pimavanserin tartrate” for ACADIA’s drug candidate ACP-103.
